Skip to content
value.today

Akoya Biosciences, Inc.

Total raised
$34 M
2 rounds on record
Latest round
$25 M
Sep 2018
First round on record
Jul 2017
Today
Acquired
Acquired by Quanterix Corporation

Acquired

Matched to this startup by its exact name; the buyer's report is the source.

Acquisition of Akoya Biosciences, Inc.
AcquiredBuyerAcquisition dateCompletionPriceStakeSource
Akoya Biosciences, IncQuanterix Corporation2025—$151 M—Annual report

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Akoya Biosciences, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2018$25 MNo. 2$10 to $50 million

Akoya Biosciences, Inc.: Raise no. 2, Sep 2018

Investors in this round

6 investors had bought by the notice of Oct 2, 2018: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$25 M of $26 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brian McKelligon · Executive Officer, Director
  • Rob Hart · Executive Officer
  • Garry Nolan · Director
  • Matthew Winkler · Director
  • Robert Shepler · Director
  • Thomas Raffin · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Brian McKelligon, Chief Executive Officer. Newest notice filed Oct 2, 2018. Read the notice at the SEC.

equitySEC
Jul 2017$9 MNo. 1$2 to $10 million

Akoya Biosciences, Inc.: Raise no. 1, Jul 2017

Investors in this round

6 investors had bought by the notice of Jul 14, 2017: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$9 M of $9 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brian McKelligon · Executive Officer
  • Rob Hart · Executive Officer
  • Garry Nolan · Director
  • Matthew Winkler · Director
  • Robert Shepler · Director
  • Thomas Raffin · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Rob Hart, Chief Financial Officer. Newest notice filed Jul 14, 2017. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Akoya Biosciences, Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2018).

    SEC Form D · Oct 2018

  • The industry group it chose in its notices: Other.

    SEC Form D · Oct 2018

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Akoya Biosciences, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Akoya Biosciences, Inc.
NameRoleNamed in
Brian McKelligonExecutive officerOct 2018
Rob HartExecutive officerOct 2018
Brian McKelligonDirectorOct 2018
Garry NolanDirectorOct 2018
Matthew WinklerDirectorOct 2018
Robert SheplerDirectorOct 2018
Thomas RaffinDirectorOct 2018

Acquired (Jan 1, 2025). Acquired by Quanterix Corporation.